Meropenem, anhydrous

Meropenem, anhydrous Brand names, Meropenem, anhydrous Analogs

Meropenem, anhydrous Brand Names Mixture

No information avaliable

Meropenem, anhydrous Chemical_Formula

C₉H₁₁Cl₂N₃O₄S₂

Meropenem, anhydrous RX_link

http://www.rxlist.com/cgi/generic3/methyclothiazide.htm

Meropenem, anhydrous fda sheet

Meropenem, anhydrous msds (material safety sheet)

Meropenem,_anhydrous MSDS

Meropenem, anhydrous Synthesis Reference

No information avaliable

Meropenem, anhydrous Molecular Weight

360.239 g/mol

Meropenem, anhydrous Melting Point

225 ^oC

Meropenem, anhydrous H₂O Solubility

11.2 mg/L

Meropenem, anhydrous State

Solid

Meropenem, anhydrous LogP

0.604

Meropenem, anhydrous Dosage Forms

Tablet for oral administration (5 mg)

Meropenem, anhydrous Indication

For use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

Meropenem, anhydrous Pharmacology

Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs.

Meropenem, anhydrous Absorption

Rapidly absorbed following oral administration.

Meropenem, anhydrous side effects and Toxicity

Acute oral toxicity (LD₅₀): >4000 mg/kg [Rat]. Symptoms of overdosage include electrolyte imbalance and signs of potassium deficiency such as confusion, dizziness, muscular weakness, and gastrointestinal disturbances.

Meropenem, anhydrous Patient Information